|Expense Ratio (net)||1.83%|
|Category||Foreign Large Growth|
|Last Cap Gain||1.00|
|Morningstar Risk Rating||Average|
|Beta (5Y Monthly)||0.89|
|5y Average Return||N/A|
|Average for Category||N/A|
|Inception Date||Apr 17, 1995|
Bristol Myers Squibb and Exelixis announced Monday that the FDA had granted priority review for their combined treatment for a form of advanced kidney cancer; and BMY stock, EXEL stock rose.
US FDA Accepts for Priority Review Applications for OPDIVO® in Combination with CABOMETYX® in Advanced Renal Cell Carcinoma
Exelixis, Inc. (Nasdaq: EXEL) and Aurigene Discovery Technologies Limited (Aurigene) today disclosed new preclinical data showing that AUR102 has potent anti-tumor activity in a large panel of cancer cell lines. AUR102 is a potent, selective, and orally bioavailable covalent inhibitor of cyclin-dependent kinase 7 (CDK7), which is an important regulator of the cellular transcriptional and cell cycle machinery. Exelixis has an exclusive option for AUR102 under its July 2019 exclusive collaboration, option and license agreement with Aurigene. The new data will be presented in a poster (Abstract 170) at the 32nd EORTC-NCI-AACR (ENA) Symposium, which is being held virtually on October 24-25, 2020.